{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:45:01Z","timestamp":1788446701049,"version":"build-2803163510"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,21]]},"DOI":"10.7759\/cureus.88412","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T09:45:01Z","timestamp":1753091101000},"source":"Crossref","is-referenced-by-count":5,"title":["Consensus on the Use of Mefenamic Acid in Pediatric Practice: Perspectives From Indian Pediatricians"],"prefix":"10.7759","author":[{"given":"Uday","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravishankar A","family":"Venkata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Charde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K K","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Sanklecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylapore V","family":"Suresh Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Niranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Dudhgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikrishna","family":"Surampudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitha","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhor  V","family":"Borkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007365","article-title":"Workload and management of childhood fever at general practice out-of-hours care: an observational cohort study","volume":"5","author":"de Bont EG","year":"2015","unstructured":"de Bont EG, Lepot JM, Hendrix DA, Loonen N, Guldemond-Hecker Y, Dinant GJ, Cals JW. Workload and management of childhood fever at general practice out-of-hours care: an observational cohort study. BMJ Open. 2015, 5:e007365. 10.1136\/bmjopen-2014-007365","journal-title":"BMJ Open"},{"key":"ref2","article-title":"Pyrogenic cytokines mediated pathophysiology of fever and role of mefenamic acid in pediatric practice","volume":"32","author":"Gambhir A","year":"2021","unstructured":"Gambhir A, Tamboli S, Prasad SM, Inamdar NR. Pyrogenic cytokines mediated pathophysiology of fever and role of mefenamic acid in pediatric practice. Indian J Clin Pract. 2021, 32:229-36.","journal-title":"Indian J Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083469","article-title":"Managing fever in children: a national survey of parents' knowledge and practices in France","volume":"8","author":"Bertille N","year":"2013","unstructured":"Bertille N, Fournier-Charri\u00e8re E, Pons G, Chalumeau M. Managing fever in children: a national survey of parents' knowledge and practices in France. PLoS One. 2013, 8:e83469. 10.1371\/journal.pone.0083469","journal-title":"PLoS One"},{"key":"ref4","article-title":"Mefenamic acid: the evolution of a versatile NSAID","volume":"32","author":"Tripathi SK","year":"2021","unstructured":"Tripathi SK, Kasture PN. Mefenamic acid: the evolution of a versatile NSAID. Indian J Clin Pract. 2021, 32:115-23.","journal-title":"Indian J Clin Pract"},{"key":"ref5","article-title":"Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy","volume":"13","author":"Melnikov V","year":"2021","unstructured":"Melnikov V, Tiburcio-Jimenez D, Mendoza-Hernandez MA, et al.. Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy. Am J Transl Res. 2021, 13:4535-43.","journal-title":"Am J Transl Res"},{"key":"ref6","article-title":"Use of mefenamic acid as a supportive treatment of COVID-19: a repurposing drug","volume":"9","author":"Pareek RP","year":"2020","unstructured":"Pareek RP. Use of mefenamic acid as a supportive treatment of COVID-19: a repurposing drug. Int J Sci Res. 2020, 9:69-73.","journal-title":"Int J Sci Res"},{"key":"ref7","article-title":"Repurposing mefenamic acid in the management of COVID-19","volume":"119","author":"Aggarwal KK","year":"2021","unstructured":"Aggarwal KK, Woei Chong Y, Sharma R, et al.. Repurposing mefenamic acid in the management of COVID-19. J Indian Med Assoc. 2021, 119:16-23.","journal-title":"J Indian Med Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/aet2.10891","article-title":"Educator's blueprint: a primer on consensus methods in medical education research","volume":"7","author":"Gottlieb M","year":"2023","unstructured":"Gottlieb M, Caretta-Weyer H, Chan TM, Humphrey-Murto S. Educator's blueprint: a primer on consensus methods in medical education research. AEM Educ Train. 2023, 7:e10891. 10.1002\/aet2.10891","journal-title":"AEM Educ Train"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa P","year":"2021","unstructured":"Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021, 11:116-29. 10.5662\/wjm.v11.i4.116","journal-title":"World J Methodol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.13.15","article-title":"The potential and promise of mefenamic acid","volume":"6","author":"Cimolai N","year":"2013","unstructured":"Cimolai N. The potential and promise of mefenamic acid. Expert Rev Clin Pharmacol. 2013, 6:289-305. 10.1586\/ecp.13.15","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/219864a0","article-title":"Antagonism by fenamates of prostaglandin F2\u03b1 and of slow reacting substance on human bronchial muscle","volume":"219","author":"Collier HO","year":"1968","unstructured":"Collier HO, Sweatman WJ. Antagonism by fenamates of prostaglandin F2\u03b1 and of slow reacting substance on human bronchial muscle. Nature. 1968, 219:864-5. 10.1038\/219864a0","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1971.tb07172.x","article-title":"Selective blockade of the vasodepressor response to prostaglandin F2\u03b1 in the anaesthetized rabbit","volume":"43","author":"Levy B","year":"1971","unstructured":"Levy B, Lindner HR. Selective blockade of the vasodepressor response to prostaglandin F2\u03b1 in the anaesthetized rabbit. Br J Pharmacol. 1971, 43:236-41. 10.1111\/j.1476-5381.1971.tb07172.x","journal-title":"Br J Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-6980(74)80007-9","article-title":"Studies of prostaglandins and prostaglandin antagonists on bovine pulmonary vein in vitro","volume":"6","author":"Burka JF","year":"1974","unstructured":"Burka JF, Eyre P. Studies of prostaglandins and prostaglandin antagonists on bovine pulmonary vein in vitro. Prostaglandins. 1974, 6:333-43. 10.1016\/s0090-6980(74)80007-9","journal-title":"Prostaglandins"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(98)00091-6","article-title":"Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs","volume":"104","author":"Cryer B","year":"1998","unstructured":"Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998, 104:413-21. 10.1016\/s0002-9343(98)00091-6","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1073858418760481","article-title":"Neural mechanisms of inflammation-induced fever","volume":"24","author":"Blomqvist A","year":"2018","unstructured":"Blomqvist A, Engblom D. Neural mechanisms of inflammation-induced fever. Neuroscientist. 2018, 24:381-99. 10.1177\/1073858418760481","journal-title":"Neuroscientist"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1566-0702(00)00220-4","article-title":"Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?","volume":"85","author":"Dantzer R","year":"2000","unstructured":"Dantzer R, Konsman JP, Bluth\u00e9 RM, Kelley KW. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?. Auton Neurosci. 2000, 85:60-5. 10.1016\/S1566-0702(00)00220-4","journal-title":"Auton Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti E","year":"2011","unstructured":"Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011, 31:986-1000. 10.1161\/ATVBAHA.110.207449","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.06.008","article-title":"Mechanisms and therapeutic relevance of neuro-immune communication","volume":"46","author":"Chavan SS","year":"2017","unstructured":"Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity. 2017, 46:927-42. 10.1016\/j.immuni.2017.06.008","journal-title":"Immunity"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1290439","article-title":"Meclofenamate inhibits prostaglandin E binding and adenylyl cyclase activation in human myometrium","volume":"129","author":"L\u00f3pez Bernal A","year":"1991","unstructured":"L\u00f3pez Bernal A, Buckley S, Rees CM, Marshall JM. Meclofenamate inhibits prostaglandin E binding and adenylyl cyclase activation in human myometrium. J Endocrinol. 1991, 129:439-45. 10.1677\/joe.0.1290439","journal-title":"J Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models","volume":"7","author":"Daniels MJ","year":"2016","unstructured":"Daniels MJ, Rivers-Auty J, Schilling T, et al.. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat Commun. 2016, 7:12504. 10.1038\/ncomms12504","journal-title":"Nat Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02058.x","article-title":"Pharmacological comparison of novel synthetic fenamate analogues with econazole and 2-APB on the inhibition of TRPM2 channels","volume":"167","author":"Chen GL","year":"2012","unstructured":"Chen GL, Zeng B, Eastmond S, Elsenussi SE, Boa AN, Xu SZ. Pharmacological comparison of novel synthetic fenamate analogues with econazole and 2-APB on the inhibition of TRPM2 channels. Br J Pharmacol. 2012, 167:1232-43. 10.1111\/j.1476-5381.2012.02058.x","journal-title":"Br J Pharmacol"},{"key":"ref22","article-title":"Inflammasome, inflammation, infection and mefenamic acid","volume":"70","author":"Kasture P","year":"2022","unstructured":"Kasture P, Mehta K, Gowda A. Inflammasome, inflammation, infection and mefenamic acid. J Assoc Physicians India. 2022, 70:11-2.","journal-title":"J Assoc Physicians India"},{"key":"ref23","article-title":"Evaluation of efficacy and tolerability of acetaminophen (paracetamol) and mefenamic acid as antipyretic in pediatric patients with febrile illness: a comparative study","volume":"2","author":"Kunkulol RR","year":"2013","unstructured":"Kunkulol RR, Chavan AU, Chavva AK. Evaluation of efficacy and tolerability of acetaminophen (paracetamol) and mefenamic acid as antipyretic in pediatric patients with febrile illness: a comparative study. Int J Med Res Health Sci. 2013, 2:23-9.","journal-title":"Int J Med Res Health Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398690","article-title":"Current problems with non-specific COX inhibitors","volume":"6","author":"McGettigan P","year":"2000","unstructured":"McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des. 2000, 6:1693-724. 10.2174\/1381612003398690","journal-title":"Curr Pharm Des"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-2242-0.00026-2","article-title":"Nonopioid analgesics: NSAIDs, COX-2 inhibitors, and acetaminophen","author":"Williams BS","year":"2011","unstructured":"Williams BS, Buvanendran A. Nonopioid analgesics: NSAIDs, COX-2 inhibitors, and acetaminophen. Essentials of Pain Medicine. Elsevier\/Saunders, Philadelphia (PA); 2011. 130-9. 10.1016\/B978-1-4377-2242-0.00026-2"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102240","article-title":"Interpreting the benefit and risk data in between-drug comparisons: illustration of the challenges using the example of mefenamic acid versus ibuprofen","volume":"14","author":"Farkouh A","year":"2022","unstructured":"Farkouh A, Hemetsberger M, Noe CR, Baumg\u00e4rtel C. Interpreting the benefit and risk data in between-drug comparisons: illustration of the challenges using the example of mefenamic acid versus ibuprofen. Pharmaceutics. 2022, 14:2240. 10.3390\/pharmaceutics14102240","journal-title":"Pharmaceutics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001463","article-title":"Comparative plasma and cerebrospinal fluid pharmacokinetics of paracetamol after intravenous and oral administration","volume":"123","author":"Langford RA","year":"2016","unstructured":"Langford RA, Hogg M, Bjorksten AR, Williams DL, Leslie K, Jamsen K, Kirkpatrick C. Comparative plasma and cerebrospinal fluid pharmacokinetics of paracetamol after intravenous and oral administration. Anesth Analg. 2016, 123:610-5. 10.1213\/ANE.0000000000001463","journal-title":"Anesth Analg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/23328940.2021.1886392","article-title":"Paracetamol (acetaminophen): a familiar drug with an unexplained mechanism of action","volume":"8","author":"Ayoub SS","year":"2021","unstructured":"Ayoub SS. Paracetamol (acetaminophen): a familiar drug with an unexplained mechanism of action. Temperature (Austin). 2021, 8:351-71. 10.1080\/23328940.2021.1886392","journal-title":"Temperature (Austin)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04402.x","article-title":"Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum","volume":"75","author":"Kulo A","year":"2013","unstructured":"Kulo A, Peeters MY, Allegaert K, et al.. Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum. Br J Clin Pharmacol. 2013, 75:850-60. 10.1111\/j.1365-2125.2012.04402.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1039\/c7tx00340d","article-title":"Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective","volume":"7","author":"Athersuch TJ","year":"2018","unstructured":"Athersuch TJ, Antoine DJ, Boobis AR, et al.. Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. Toxicol Res (Camb). 2018, 7:347-57. 10.1039\/c7tx00340d","journal-title":"Toxicol Res (Camb)"},{"key":"ref31","article-title":"Martindale: The Complete Drug Reference","year":"2014","unstructured":"Martindale. The Complete Drug Reference. Brayfield A (ed): Pharmaceutical Press,  London (UK); 2014."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: pharmacology, efficacy and safety","volume":"17","author":"Rainsford KD","year":"2009","unstructured":"Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009, 17:275-342. 10.1007\/s10787-009-0016-x","journal-title":"Inflammopharmacology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.afjem.2020.11.004","article-title":"Management of acute fever in children: consensus recommendations for community and primary healthcare providers in sub-Saharan Africa","volume":"11","author":"Green R","year":"2021","unstructured":"Green R, Webb D, Jeena PM, et al.. Management of acute fever in children: consensus recommendations for community and primary healthcare providers in sub-Saharan Africa. Afr J Emerg Med. 2021, 11:283-96. 10.1016\/j.afjem.2020.11.004","journal-title":"Afr J Emerg Med"},{"key":"ref34","unstructured":"MEFTAL\u00ae-P suspension. (2023). Accessed. 2025: https:\/\/meftal.com\/assets\/MEFTAL-P-Suspension.pdf."},{"key":"ref35","unstructured":"MEFTAL\u00ae-250 DT and MEFTAL\u00ae-500 tablets. (2022). Accessed. 2025: https:\/\/meftal.com\/assets\/MEFTAL-250-DT.pdf."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12628","article-title":"Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review","volume":"80","author":"Moore RA","year":"2015","unstructured":"Moore RA, Derry S, Wiffen PJ, Straube S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Br J Clin Pharmacol. 2015, 80:381-8. 10.1111\/bcp.12628","journal-title":"Br J Clin Pharmacol"},{"key":"ref37","unstructured":"Mefenamic acid 50 mg\/5 ml suspension. (2023). Accessed. 2025: https:\/\/www.medicines.org.uk\/emc\/product\/13316\/smpc."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3852","article-title":"Fever and antipyretic use in children","volume":"127","author":"Sullivan JE","year":"2011","unstructured":"Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics. 2011, 127:580-7. 10.1542\/peds.2010-3852","journal-title":"Pediatrics"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05753-7","article-title":"Definition and assessment of fever-related discomfort in pediatric literature: a systematic review","volume":"183","author":"Milani GP","year":"2024","unstructured":"Milani GP, Alberti I, Bonetti A, Garattini S, Corsello A, Marchisio P, Chiappini E. Definition and assessment of fever-related discomfort in pediatric literature: a systematic review. Eur J Pediatr. 2024, 183:4969-79. 10.1007\/s00431-024-05753-7","journal-title":"Eur J Pediatr"},{"key":"ref40","article-title":"Randomized open-label study to compare the safety and efficacy of paracetamol, ibuprofen, and mefenamic acid in febrile children","volume":"8","author":"Reddy GT","year":"2020","unstructured":"Reddy GT, Gobbur RH, Patil SV. Randomized open-label study to compare the safety and efficacy of paracetamol, ibuprofen, and mefenamic acid in febrile children. Int J Sci Stud. 2020, 8:58-62.","journal-title":"Int J Sci Stud"},{"key":"ref41","article-title":"Choice of antipyretic in children","volume":"43","author":"Khubchandani RP","year":"1995","unstructured":"Khubchandani RP, Ghatikar KN, Keny S, Usgaonkar NG. Choice of antipyretic in children. J Assoc Physicians India. 1995, 43:614-6.","journal-title":"J Assoc Physicians India"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26733","article-title":"The antipyretic effect of high-dose paracetamol versus mefenamic acid in the treatment of febrile children: a randomized control trial","volume":"14","author":"Loya A","year":"2022","unstructured":"Loya A, Siddiqui MS, Sangle A, Ingale V, Saha S, Nelanuthala M. The antipyretic effect of high-dose paracetamol versus mefenamic acid in the treatment of febrile children: a randomized control trial. Cureus. 2022, 14:e26733. 10.7759\/cureus.26733","journal-title":"Cureus"},{"key":"ref43","article-title":"Mefenamic acid is an effective and well tolerated antipyretic for children","volume":"55","author":"Dabholkar KM","year":"2002","unstructured":"Dabholkar KM. Mefenamic acid is an effective and well tolerated antipyretic for children. Ind Pract. 2002, 55:291-6.","journal-title":"Ind Pract"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/25151355231216122","article-title":"Efficacy of oral mefenamic acid versus paracetamol as a prophylactic analgesic for needle pain in children receiving vaccination: a three-arm, parallel, triple-blind, placebo-controlled MAP VaC randomized controlled trial","volume":"11","author":"Pasi R","year":"2023","unstructured":"Pasi R, Babu TA, Kallidoss VK. Efficacy of oral mefenamic acid versus paracetamol as a prophylactic analgesic for needle pain in children receiving vaccination: a three-arm, parallel, triple-blind, placebo-controlled MAP VaC randomized controlled trial. Ther Adv Vaccines Immunother. 2023, 11:25151355231216122. 10.1177\/25151355231216122","journal-title":"Ther Adv Vaccines Immunother"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials","volume":"374","author":"Prymula R","year":"2009","unstructured":"Prymula R, Siegrist CA, Chlibek R, et al.. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009, 374:1339-50. 10.1016\/S0140-6736(09)61208-3","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1177\/1744806918770320","article-title":"Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: a network meta-analysis","volume":"14","author":"Feng X","year":"2018","unstructured":"Feng X, Wang X. Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: a network meta-analysis. Mol Pain. 2018, 14:1744806918770320. 10.1177\/1744806918770320","journal-title":"Mol Pain"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600750914","article-title":"Bioavailability of mefenamic acid: influence of food and water intake","volume":"75","author":"Hamaguchi T","year":"1986","unstructured":"Hamaguchi T, Shinkuma D, Yamanaka Y, Mizuno N. Bioavailability of mefenamic acid: influence of food and water intake. J Pharm Sci. 1986, 75:891-3. 10.1002\/jps.2600750914","journal-title":"J Pharm Sci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4663","article-title":"Comparative safety of NSAIDs for gastrointestinal events in Asia-Pacific populations: a multi-database, international cohort study","volume":"27","author":"Lai EC","year":"2018","unstructured":"Lai EC, Shin JY, Kubota K, et al.. Comparative safety of NSAIDs for gastrointestinal events in Asia-Pacific populations: a multi-database, international cohort study. Pharmacoepidemiol Drug Saf. 2018, 27:1223-30. 10.1002\/pds.4663","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-JBN-2018-0107","article-title":"Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs","volume":"41","author":"Lucas GN","year":"2019","unstructured":"Lucas GN, Leit\u00e3o AC, Alencar RL, Xavier RM, Daher EF, Silva Junior GB. Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Bras Nefrol. 2019, 41:124-30. 10.1590\/2175-8239-JBN-2018-0107","journal-title":"J Bras Nefrol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ph3072291","article-title":"Nonsteroidal anti-inflammatory drugs and the kidney","volume":"3","author":"H\u00f6rl WH","year":"2010","unstructured":"H\u00f6rl WH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals (Basel). 2010, 3:2291-321. 10.3390\/ph3072291","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13169","article-title":"Central nervous system toxicity of mefenamic acid overdose compared with other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service","volume":"83","author":"Kamour A","year":"2017","unstructured":"Kamour A, Crichton S, Cooper G, et al.. Central nervous system toxicity of mefenamic acid overdose compared with other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service. Br J Clin Pharmacol. 2017, 83:855-62. 10.1111\/bcp.13169","journal-title":"Br J Clin Pharmacol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00064","article-title":"Mechanisms underlying neuroprotection by the NSAID mefenamic acid in an experimental model of stroke","volume":"13","author":"Khansari PS","year":"2019","unstructured":"Khansari PS, Halliwell RF. Mechanisms underlying neuroprotection by the NSAID mefenamic acid in an experimental model of stroke. Front Neurosci. 2019, 13:64. 10.3389\/fnins.2019.00064","journal-title":"Front Neurosci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1385523","article-title":"Antiseizure properties of fenamate NSAIDs determined in mature human stem-cell derived neuroglial circuits","volume":"15","author":"Salmanzadeh H","year":"2024","unstructured":"Salmanzadeh H, Halliwell RF. Antiseizure properties of fenamate NSAIDs determined in mature human stem-cell derived neuroglial circuits. Front Pharmacol. 2024, 15:1385523. 10.3389\/fphar.2024.1385523","journal-title":"Front Pharmacol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1999.00709.x","article-title":"Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid","volume":"11","author":"Halliwell RF","year":"1999","unstructured":"Halliwell RF, Thomas P, Patten D, James CH, Martinez-Torres A, Miledi R, Smart TG. Subunit-selective modulation of GABAA receptors by the non-steroidal anti-inflammatory agent, mefenamic acid. Eur J Neurosci. 1999, 11:2897-905. 10.1046\/j.1460-9568.1999.00709.x","journal-title":"Eur J Neurosci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2009.06.014","article-title":"Evidence for neuroprotection by the fenamate NSAID, mefenamic acid","volume":"55","author":"Khansari PS","year":"2009","unstructured":"Khansari PS, Halliwell RF. Evidence for neuroprotection by the fenamate NSAID, mefenamic acid. Neurochem Int. 2009, 55:683-8. 10.1016\/j.neuint.2009.06.014","journal-title":"Neurochem Int"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2017.00063","article-title":"NLRP3 inflammasome in neurological diseases, from functions to therapies","volume":"11","author":"Song L","year":"2017","unstructured":"Song L, Pei L, Yao S, Wu Y, Shang Y. NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci. 2017, 11:63. 10.3389\/fncel.2017.00063","journal-title":"Front Cell Neurosci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-015-0489-0","article-title":"Prevalence of prescribing in pregnancy using the Irish primary care research network: a pilot study","volume":"15","author":"Dillon P","year":"2015","unstructured":"Dillon P, O'Brien KK, McDonnell R, et al.. Prevalence of prescribing in pregnancy using the Irish primary care research network: a pilot study. BMC Pregnancy Childbirth. 2015, 15:67. 10.1186\/s12884-015-0489-0","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.3.776","article-title":"The transfer of drugs and other chemicals into human milk","volume":"108","year":"2001","unstructured":"The transfer of drugs and other chemicals into human milk. Pediatrics. 2001, 108.776-89. 10.1542\/peds.108.3.776","journal-title":"Pediatrics"},{"key":"ref59","article-title":"The breast milk excretion of mefenamic acid","volume":"10","author":"Buchanan RA","year":"1968","unstructured":"Buchanan RA, Eaton CJ, Koeff ST, Kinkel AW. The breast milk excretion of mefenamic acid. Curr Ther Res Clin Exp. 1968, 10:592-7.","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31828a4b54","article-title":"Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation","volume":"116","author":"Bloor M","year":"2013","unstructured":"Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013, 116:1063-75. 10.1213\/ANE.0b013e31828a4b54","journal-title":"Anesth Analg"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp16X684433","article-title":"The dangers of NSAIDs: look both ways","volume":"66","author":"Davis A","year":"2016","unstructured":"Davis A, Robson J. The dangers of NSAIDs: look both ways. Br J Gen Pract. 2016, 66:172-3. 10.3399\/bjgp16X684433","journal-title":"Br J Gen Pract"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04050.x","article-title":"Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis","volume":"35","author":"Schafer AI","year":"1995","unstructured":"Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995, 35:209-19. 10.1002\/j.1552-4604.1995.tb04050.x","journal-title":"J Clin Pharmacol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/molecules19022089","article-title":"Antiplatelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit","volume":"19","author":"Chelucci RC","year":"2014","unstructured":"Chelucci RC, Dutra LA, Lopes Pires ME, de Melo TR, Bosquesi PL, Chung MC, Dos Santos JL. Antiplatelet and antithrombotic activities of non-steroidal anti-inflammatory drugs containing an N-acyl hydrazone subunit. Molecules. 2014, 19:2089-99. 10.3390\/molecules19022089","journal-title":"Molecules"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.458","article-title":"Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis","volume":"41","author":"Knijff-Dutmer EA","year":"2002","unstructured":"Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002, 41:458-61. 10.1093\/rheumatology\/41.4.458","journal-title":"Rheumatology (Oxford)"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(92)91614-g","article-title":"Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia","volume":"166","author":"van Eijkeren MA","year":"1992","unstructured":"van Eijkeren MA, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol. 1992, 166:1419-28. 10.1016\/0002-9378(92)91614-g","journal-title":"Am J Obstet Gynecol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11509","article-title":"Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: a randomized controlled trial","volume":"19","author":"Guzman-Esquivel J","year":"2020","unstructured":"Guzman-Esquivel J, Mendoza-Hernandez MA, Tiburcio-Jimenez D, et al.. Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: a randomized controlled trial. Oncol Lett. 2020, 19:4151-60. 10.3892\/ol.2020.11509","journal-title":"Oncol Lett"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4063562","article-title":"NLRP3 inflammasome and inflammatory diseases","volume":"2020","author":"Wang Z","year":"2020","unstructured":"Wang Z, Zhang S, Xiao Y, et al.. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev. 2020, 2020:4063562. 10.1155\/2020\/4063562","journal-title":"Oxid Med Cell Longev"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5238","article-title":"Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (review)","volume":"51","author":"Zhang X","year":"2023","unstructured":"Zhang X, Wang Z, Zheng Y, et al.. Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (review). Int J Mol Med. 2023, 51:35. 10.3892\/ijmm.2023.5238","journal-title":"Int J Mol Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.02.011","article-title":"Inflammasome biology, molecular pathology and therapeutic implications","volume":"187","author":"Awad F","year":"2018","unstructured":"Awad F, Assrawi E, Louvrier C, et al.. Inflammasome biology, molecular pathology and therapeutic implications. Pharmacol Ther. 2018, 187:133-49. 10.1016\/j.pharmthera.2018.02.011","journal-title":"Pharmacol Ther"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.04.023","article-title":"Cytokine levels in febrile seizure patients: a systematic review and meta-analysis","volume":"59","author":"Kwon A","year":"2018","unstructured":"Kwon A, Kwak BO, Kim K, et al.. Cytokine levels in febrile seizure patients: a systematic review and meta-analysis. Seizure. 2018, 59:5-10. 10.1016\/j.seizure.2018.04.023","journal-title":"Seizure"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2019.12.013","article-title":"Increased levels of NLRP3 in children with febrile seizures","volume":"42","author":"Liu Z","year":"2020","unstructured":"Liu Z, Xian H, Ye X, Chen J, Ma Y, Huang W. Increased levels of NLRP3 in children with febrile seizures. Brain Dev. 2020, 42:336-41. 10.1016\/j.braindev.2019.12.013","journal-title":"Brain Dev"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.09.007","article-title":"Response of host inflammasomes to viral infection","volume":"23","author":"Chen IY","year":"2015","unstructured":"Chen IY, Ichinohe T. Response of host inflammasomes to viral infection. Trends Microbiol. 2015, 23:55-63. 10.1016\/j.tim.2014.09.007","journal-title":"Trends Microbiol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00489","article-title":"Inflammasome fuels dengue severity","volume":"10","author":"Shrivastava G","year":"2020","unstructured":"Shrivastava G, Valenzuela Leon PC, Calvo E. Inflammasome fuels dengue severity. Front Cell Infect Microbiol. 2020, 10:489. 10.3389\/fcimb.2020.00489","journal-title":"Front Cell Infect Microbiol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003031.pub4","article-title":"Prophylactic drug management for febrile seizures in children","volume":"6","author":"Offringa M","year":"2021","unstructured":"Offringa M, Newton R, Nevitt SJ, Vraka K. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev. 2021, 6:CD003031. 10.1002\/14651858.CD003031.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.30491\/ijmr.2021.275730.1193","article-title":"NSAIDs: a double edged sword in viral infections","volume":"9","author":"Gerges RH","year":"2022","unstructured":"Gerges RH. NSAIDs: a double edged sword in viral infections. Int J Med Rev. 2022, 9:288-97. 10.30491\/ijmr.2021.275730.1193","journal-title":"Int J Med Rev"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040990","article-title":"Adverse effects of non-steroidal anti-inflammatory drugs in patients with viral respiratory infections: rapid systematic review","volume":"10","author":"von Philipsborn P","year":"2020","unstructured":"von Philipsborn P, Biallas R, Burns J, et al.. Adverse effects of non-steroidal anti-inflammatory drugs in patients with viral respiratory infections: rapid systematic review. BMJ Open. 2020, 10:e040990. 10.1136\/bmjopen-2020-040990","journal-title":"BMJ Open"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.03.069","article-title":"Does the use of antipyretics in children who have acute infections prolong febrile illness? A systematic review and meta-analysis","volume":"163","author":"Purssell E","year":"2013","unstructured":"Purssell E, While AE. Does the use of antipyretics in children who have acute infections prolong febrile illness? A systematic review and meta-analysis. J Pediatr. 2013, 163:822-7.e1-2. 10.1016\/j.jpeds.2013.03.069","journal-title":"J Pediatr"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.925","article-title":"Nonsteroidal anti-inflammatory drugs in acute viral respiratory tract infections: an updated systematic review","volume":"10","author":"Azh N","year":"2022","unstructured":"Azh N, Barzkar F, Motamed-Gorji N, et al.. Nonsteroidal anti-inflammatory drugs in acute viral respiratory tract infections: an updated systematic review. Pharmacol Res Perspect. 2022, 10:e00925. 10.1002\/prp2.925","journal-title":"Pharmacol Res Perspect"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000001024","article-title":"NSAIDs for early management of acute respiratory infections","volume":"37","author":"Bassetti M","year":"2024","unstructured":"Bassetti M, Andreoni M, Santus P, Scaglione F. NSAIDs for early management of acute respiratory infections. Curr Opin Infect Dis. 2024, 37:304-11. 10.1097\/QCO.0000000000001024","journal-title":"Curr Opin Infect Dis"},{"key":"ref80","article-title":"Study the antiviral activity of some derivatives of tetracycline and non-steroid anti inflammatory drugs towards dengue virus","volume":"30","author":"Rothan HA","year":"2013","unstructured":"Rothan HA, Buckle MJ, Ammar YA, Mohammadjavad P, Shatrah O, Noorsaadah AR, Rohana Y. Study the antiviral activity of some derivatives of tetracycline and non-steroid anti inflammatory drugs towards dengue virus. Trop Biomed. 2013, 30:681-90.","journal-title":"Trop Biomed"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.01.006","article-title":"Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo","volume":"127","author":"Rothan HA","year":"2016","unstructured":"Rothan HA, Bahrani H, Abdulrahman AY, et al.. Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo. Antiviral Res. 2016, 127:50-6. 10.1016\/j.antiviral.2016.01.006","journal-title":"Antiviral Res"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00996-19","article-title":"Dengue virus M protein promotes NLRP3 inflammasome activation to induce vascular leakage in mice","volume":"93","author":"Pan P","year":"2019","unstructured":"Pan P, Zhang Q, Liu W, et al.. Dengue virus M protein promotes NLRP3 inflammasome activation to induce vascular leakage in mice. J Virol. 2019, 93:e00996-19. 10.1128\/JVI.00996-19","journal-title":"J Virol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2009.00148.x","article-title":"Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness","volume":"53","author":"Jaiyen Y","year":"2009","unstructured":"Jaiyen Y, Masrinoul P, Kalayanarooj S, Pulmanausahakul R, Ubol S. Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness. Microbiol Immunol. 2009, 53:442-50. 10.1111\/j.1348-0421.2009.00148.x","journal-title":"Microbiol Immunol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2017.1356540","article-title":"NS2A comprises a putative viroporin of dengue virus 2","volume":"8","author":"Shrivastava G","year":"2017","unstructured":"Shrivastava G, Garc\u00eda-Cordero J, Le\u00f3n-Ju\u00e1rez M, Oza G, Tapia-Ram\u00edrez J, Villegas-Sepulveda N, Cedillo-Barr\u00f3n L. NS2A comprises a putative viroporin of dengue virus 2. Virulence. 2017, 8:1450-6. 10.1080\/21505594.2017.1356540","journal-title":"Virulence"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00352","article-title":"Dengue virus serotype 2 and its non-structural proteins 2A and 2B activate NLRP3 inflammasome","volume":"11","author":"Shrivastava G","year":"2020","unstructured":"Shrivastava G, Visoso-Carvajal G, Garcia-Cordero J, et al.. Dengue virus serotype 2 and its non-structural proteins 2A and 2B activate NLRP3 inflammasome. Front Immunol. 2020, 11:352. 10.3389\/fimmu.2020.00352","journal-title":"Front Immunol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.616394","article-title":"Exposure of platelets to dengue virus and envelope protein domain III induces NLRP3 inflammasome-dependent platelet cell death and thrombocytopenia in mice","volume":"12","author":"Lien TS","year":"2021","unstructured":"Lien TS, Chan H, Sun DS, Wu JC, Lin YY, Lin GL, Chang HH. Exposure of platelets to dengue virus and envelope protein domain III induces NLRP3 inflammasome-dependent platelet cell death and thrombocytopenia in mice. Front Immunol. 2021, 12:616394. 10.3389\/fimmu.2021.616394","journal-title":"Front Immunol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504449","article-title":"Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation","volume":"122","author":"Hottz ED","year":"2013","unstructured":"Hottz ED, Lopes JF, Freitas C, et al.. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood. 2013, 122:3405-14. 10.1182\/blood-2013-05-504449","journal-title":"Blood"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva LA","year":"2017","unstructured":"Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017, 127:737-49. 10.1172\/JCI84417","journal-title":"J Clin Invest"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911740","article-title":"Cytokine storm-definition, causes, and implications","volume":"23","author":"Jarczak D","year":"2022","unstructured":"Jarczak D, Nierhaus A. Cytokine storm-definition, causes, and implications. Int J Mol Sci. 2022, 23:11740. 10.3390\/ijms231911740","journal-title":"Int J Mol Sci"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01021","article-title":"Novel coronavirus-induced NLRP3 inflammasome activation: a potential drug target in the treatment of COVID-19","volume":"11","author":"Shah A","year":"2020","unstructured":"Shah A. Novel coronavirus-induced NLRP3 inflammasome activation: a potential drug target in the treatment of COVID-19. Front Immunol. 2020, 11:1021. 10.3389\/fimmu.2020.01021","journal-title":"Front Immunol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2021.06.002","article-title":"The NLRP3 inflammasome and COVID-19: activation, pathogenesis and therapeutic strategies","volume":"61","author":"Zhao N","year":"2021","unstructured":"Zhao N, Di B, Xu LL. The NLRP3 inflammasome and COVID-19: activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021, 61:2-15. 10.1016\/j.cytogfr.2021.06.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref92","article-title":"Mefenamic acid as steroid-sparing antiinflammatory drug during viral phase of COVID-19: 5 case reports","volume":"31","author":"Aggarwal KK","year":"2021","unstructured":"Aggarwal KK. Mefenamic acid as steroid-sparing antiinflammatory drug during viral phase of COVID-19: 5 case reports. Indian J Clin Pract. 2021, 31:759-63.","journal-title":"Indian J Clin Pract"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000101","article-title":"Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19","volume":"109","author":"Nainu F","year":"2023","unstructured":"Nainu F, Mamada SS, Emran TB. Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19. Int J Surg. 2023, 109:109-11. 10.1097\/JS9.0000000000000101","journal-title":"Int J Surg"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5084","article-title":"Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID\u201119: a randomized double\u2011blind placebo\u2011controlled trial","volume":"49","author":"Guzman-Esquivel J","year":"2022","unstructured":"Guzman-Esquivel J, Galvan-Salazar HR, Guzman-Solorzano HP, et al.. Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID\u201119: a randomized double\u2011blind placebo\u2011controlled trial. Int J Mol Med. 2022, 49:29. 10.3892\/ijmm.2022.5084","journal-title":"Int J Mol Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.03.017","article-title":"Bradykinin in asthma: modulation of airway inflammation and remodelling","volume":"827","author":"Ricciardolo FL","year":"2018","unstructured":"Ricciardolo FL, Folkerts G, Folino A, Mognetti B. Bradykinin in asthma: modulation of airway inflammation and remodelling. Eur J Pharmacol. 2018, 827:181-8. 10.1016\/j.ejphar.2018.03.017","journal-title":"Eur J Pharmacol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.14510239","article-title":"Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma","volume":"14","author":"Kharitonov SA","year":"1999","unstructured":"Kharitonov SA, Sapienza MM, Chung KF, Barnes PJ. Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma. Eur Respir J. 1999, 14:1023-7. 10.1183\/09031936.99.14510239","journal-title":"Eur Respir J"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1963.tb01473.x","article-title":"Antagonism by mefenamic and flufenamic acids of the bronchoconstrictor action of kinins in the guinea-pig","volume":"20","author":"CO HO","year":"1963","unstructured":"CO HO, SH PG. Antagonism by mefenamic and flufenamic acids of the bronchoconstrictor action of kinins in the guinea-pig. Br J Pharmacol Chemother. 1963, 20:345-51. 10.1111\/j.1476-5381.1963.tb01473.x","journal-title":"Br J Pharmacol Chemother"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.718779","article-title":"Inhibition of the inflammasome activity of NLRP3 attenuates HDM-induced allergic asthma","volume":"12","author":"Ma M","year":"2021","unstructured":"Ma M, Li G, Qi M, Jiang W, Zhou R. Inhibition of the inflammasome activity of NLRP3 attenuates HDM-induced allergic asthma. Front Immunol. 2021, 12:718779. 10.3389\/fimmu.2021.718779","journal-title":"Front Immunol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.04.042","article-title":"Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway","volume":"75","author":"Woo DH","year":"2004","unstructured":"Woo DH, Han IS, Jung G. Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway. Life Sci. 2004, 75:2439-49. 10.1016\/j.lfs.2004.04.042","journal-title":"Life Sci"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-019-09792-w","article-title":"The synergistic effect of mefenamic acid with ionizing radiation in colon cancer","volume":"51","author":"Hosseinimehr SJ","year":"2019","unstructured":"Hosseinimehr SJ, Safavi Z, Kangarani Farahani S, Noaparst Z, Ghasemi A, Asgarian-Omran H. The synergistic effect of mefenamic acid with ionizing radiation in colon cancer. J Bioenerg Biomembr. 2019, 51:249-57. 10.1007\/s10863-019-09792-w","journal-title":"J Bioenerg Biomembr"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01618-3","article-title":"Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice","volume":"39","author":"Seyyedi R","year":"2022","unstructured":"Seyyedi R, Talebpour Amiri F, Farzipour S, Mihandoust E, Hosseinimehr SJ. Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice. Med Oncol. 2022, 39:18. 10.1007\/s12032-021-01618-3","journal-title":"Med Oncol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.2174\/1871520620666200415100614","article-title":"Anticancer potential of mefenamic acid derivatives with platelet-derived growth factor inhibitory property","volume":"20","author":"Patel SS","year":"2020","unstructured":"Patel SS, Tripathi R, Chavda VK, Savjani JK. Anticancer potential of mefenamic acid derivatives with platelet-derived growth factor inhibitory property. Anticancer Agents Med Chem. 2020, 20:998-1008. 10.2174\/1871520620666200415100614","journal-title":"Anticancer Agents Med Chem"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5480","article-title":"Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity","volume":"37","author":"Shiiba M","year":"2017","unstructured":"Shiiba M, Yamagami H, Yamamoto A, et al.. Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity. Oncol Rep. 2017, 37:2025-32. 10.3892\/or.2017.5480","journal-title":"Oncol Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380519-consensus-on-the-use-of-mefenamic-acid-in-pediatric-practice-perspectives-from-indian-pediatricians","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T09:45:04Z","timestamp":1753091104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380519-consensus-on-the-use-of-mefenamic-acid-in-pediatric-practice-perspectives-from-indian-pediatricians"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":103,"URL":"https:\/\/doi.org\/10.7759\/cureus.88412","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}